HomeDecember
Anaveon to raise CHF 110 million in oversubscribed Series B financing

Anaveon to raise CHF 110 million in oversubscribed Series B financing

by | Dec 16, 2021 | Press Releases

Anaveon, a clinical-stage immuno-oncology company, today announced that it has agreed a CHF 110 million Series B financing led by incoming investor Forbion, corner-stoned by founding investor Syncona, also joined by existing investor Novartis Venture Fund, as well as new investors, Cowen Healthcare Investments (a division of Cowen Investment Management), Pfizer Ventures and Pontifax.